Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Child Psychiatry & Human Development
Gepubliceerd in: Child Psychiatry & Human Development 5/2012

01-10-2012 | Original Article

The Role of Co-Occurring Disruptive Behavior in the Clinical Presentation of Children and Adolescents with Anxiety in the Context of Autism Spectrum Disorders

Auteurs: Eric A. Storch, Elysse B. Arnold, Anna M. Jones, Chelsea M. Ale, Jeffrey J. Wood, Jill Ehrenreich-May, Adam B. Lewin, P. Jane Mutch, Tanya K. Murphy

Gepubliceerd in: Child Psychiatry & Human Development | Uitgave 5/2012

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

This study explored the impact of disruptive behavior disorder (DBD) comorbidity on theoretically relevant correlates among 87 children and adolescents with autism spectrum disorders (ASD) and clinically significant anxiety. Relative to youth with ASD and anxiety alone, participants with ASD, anxiety, and DBD: (a) presented with significantly more severe anxiety symptoms per clinician-, parent-, and self-report; (b) were more likely to be prescribed antipsychotic medication but were no more likely to receive additional psychosocial and educational interventions; and (c) experienced significantly greater functional impairment and family interference. These results suggest that co-occurring DBD in the context of ASD and anxiety confers greater risk for heightened symptom severity and functional impairment, and may be linked with increased prescription of antipsychotic medication.
vorige artikel The Contribution of Parenting Practices and Parent Emotion Factors in Children at Risk for Disruptive Behavior Disorders
volgende artikel Parental and Late Adolescent Psychopathology: Mothers May Provide Support When Needed Most
Literatuur
1.
Sofronoff K, Attwood T, Hinton SA (2005) Randomised controlled trial of a CBT intervention for anxiety in children with Asperger syndrome. J Child Psychol Psychiatry 46(11):1152–1160PubMedCrossRef
2.
Wood JJ, Drahota A, Sze K, Har K, Chiu A, Langer DA (2009) Cognitive behavioral therapy for anxiety in children with autism spectrum disorders: a randomized, controlled trial. J Child Psychol Psychiatry 50(3):224–234PubMedCrossRef
3.
McCracken JT, McGough J, Shah B et al (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347(5):314–321PubMedCrossRef
4.
Nadeau J, Sulkowski ML, Ung D et al (2011). Treatment of anxiety in patients with Autism spectrum disorders. Neuropsychiatry 1:567–578
5.
White SW, Oswald D, Ollendick T, Scahill L (2009) Anxiety in children and adolescents with autism spectrum disorders. Clin Psychol Rev 29(3):216–229PubMedCrossRef
6.
Muris P, Steerneman P, Merckelbach H, Holdrinet I, Meesters C (1998) Comorbid anxiety symptoms in children with pervasive developmental disorders. J Anxiety Disord 12(4):387–393PubMedCrossRef
7.
Leyfer OT, Folstein SE, Bacalman S et al (2006) Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord 36(7):849–861PubMedCrossRef
8.
de Bruin EI, Ferdinand RF, Meester S, de Nijs PF, Verheij F (2007) High rates of psychiatric co-morbidity in PDD-NOS. J Autism Dev Disord 37(5):877–886PubMedCrossRef
9.
Green J, Gilchrist A, Burton D, Cox A (2000) Social and psychiatric functioning in adolescents with Asperger syndrome compared with conduct disorder. J Autism Dev Disord 30(4):279–293PubMedCrossRef
10.
Gadow KD, Devincent CJ, Drabick DA (2008) Oppositional defiant disorder as a clinical phenotype in children with autism spectrum disorder. J Autism Dev Disord 38(7):1302–1310PubMedCrossRef
11.
Mattila ML, Hurtig T, Haapsamo H et al (2010) Comorbid psychiatric disorders associated with Asperger syndrome/high-functioning autism: a community- and clinic-based study. J Autism Dev Disord 40:1080–1093PubMedCrossRef
12.
Sze K, Wood JJ (2007) Cognitive behavioral treatment of comorbid anxiety disorders and social difficulties in children with high-functioning autism: a case report. J Contemp Psychother 37:133–143CrossRef
13.
Lewin AB, Wood JJ, Gunderson S, Murphy TK, Storch EA (2011) Phenomenology of comorbid Autism Spectrum and obsessive-compulsive disorders among children. J Devel Phys Dis 23:543–553CrossRef
14.
Storch EA, Lewin AB, Geffken GR, Morgan JR, Murphy TK (2010) The role of comorbid disruptive behavior in the clinical expression of pediatric obsessive-compulsive disorder. Behav Res Ther 48:1204–1210PubMedCrossRef
15.
Almandil NB, Wong IC (2011) Review on the current use of antipsychotic drugs in children and adolescents. Arch Dis Child Educ Pract Ed 96:192–196PubMedCrossRef
16.
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302(16):1765–1773PubMedCrossRef
17.
Neuhut R, Lindenmayer JP, Silva R (2009) Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. J Child Adolesc Psychopharmacol 19(4):415–422PubMedCrossRef
18.
Drabick DA, Gadow KD, Loney J (2008) Co-occurring ODD and GAD symptom groups: source-specific syndromes and cross-informant comorbidity. J Clin Child Adolesc Psychol 37(2):314–326PubMedCrossRef
19.
Bubier JL, Drabick DA (2009) Co-occurring anxiety and disruptive behavior disorders: the roles of anxious symptoms, reactive aggression, and shared risk processes. Clin Psychol Rev 29(7):658–669PubMedCrossRef
20.
Storch EA, Merlo LJ, Larson MJ et al (2008) Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 47(5):583–592PubMedCrossRef
21.
Geller DA, Biederman J, Stewart SE et al (2003) Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials? J Child Adolesc Psychopharmacol 13(Suppl 1):S19–S29PubMedCrossRef
22.
Langley AK, Lewin AB, Bergman RL, Lee JC, Piacentini J (2010) Correlates of comorbid anxiety and externalizing disorders in childhood obsessive compulsive disorder. Eur Child Adolesc Psychiatry 19:637–645PubMedCrossRef
23.
APA (2000) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington, DC
24.
Silverman WK, Albano AM (1996) The anxiety disorders interview schedule for DSM-IV-child and parent versions. Graywinds Publications, San Antonio
25.
Silverman WK, Saavedra LM, Pina AA (2001) Test-retest reliability of anxiety symptoms and diagnoses with the Anxiety disorders interview schedule for DSM-IV: child and parent versions. J Am Acad Child Adolesc Psychiatry 40(8):937–944PubMedCrossRef
26.
Wood JJ, Piacentini JC, Bergman RL, McCracken J, Barrios V (2002) Concurrent validity of the anxiety disorders section of the anxiety disorders interview schedule for DSM-IV: child and parent versions. J Clin Child Adolesc Psychol 31:335–342PubMed
27.
RUPP (2002) The pediatric anxiety rating scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry 41(9):1061–1069CrossRef
28.
Storch EA, Wood JJ, Ehrenreich May J et al (in press). Convergent and discriminant validity and reliability of the pediatric anxiety rating scale in youth with Autism spectrum disorders. J Autism Dev Dis
29.
National Institute of Mental Health (1985) Clinical global impression scale. Psychopharmacol Bull 21:839–844
30.
Constantino J (2002) The social responsiveness scale. Western Psychological Services, Los Angeles
31.
March JS, Parker JD, Sullivan K, Stallings P, Conners CK (1997) The multidimensional anxiety scale for children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry 36(4):554–565PubMedCrossRef
32.
Wood JJ, Piacentini JC, Bergman RL, McCracken J, Barrios V (2002) Concurrent validity of the anxiety disorders section of the anxiety disorders interview schedule for DSM-IV: child and parent versions. J Clin Child Adolesc Psychol 31(3):335–342
33.
Achenbach T (2001) Manual for the ASEBA school-age forms & profiles. University of Vermont, Burlington
34.
Bird H, Andrews H, Schwab-Stone M et al (1996) Global measures of impairment for epidemiologic and clinical use with children and adolescents. Int J Meth Psychiatric Res 6:295–307CrossRef
35.
Greenland S (1987) Interpretation and choice of effect measures in epidemiologic analyses. Am J Epidem 125:761–767
36.
Barkley RA, Shelton TL, Crosswait C et al (2002) Preschool children with disruptive behavior: three-year outcome as a function of adaptive disability. Dev Psychopathol 14:45–67PubMedCrossRef
37.
Langley AK, Bergman RL, McCracken J, Piacentini JC (2004) Impairment in childhood anxiety disorders: preliminary examination of the child anxiety impact scale-parent version. J Child Adolesc Psychopharmacol 14(1):105–114PubMedCrossRef
38.
Lecavalier L, Leone S, Wiltz J (2006) The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. J Intellect Disabil Res 50(Pt 3):172–183PubMedCrossRef
39.
Arnold LE, Farmer C, Kraemer HC et al (2010) Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol 20:83–93PubMedCrossRef
40.
Lewin AB, Storch EA, Storch HD (2010) Risks from antipsychotic medications in children and adolescents. JAMA 303(8):729–730PubMedCrossRef
41.
Brosnan J, Healy O (2011) A review of behavioral interventions for the treatment of aggression in individuals with developmental disabilities. Res Dev Disabil 32:437–446PubMedCrossRef
42.
Masse J, McNeil CB, Wagner SM, Chorney DB (2007) Parent-child interaction therapy and high functioning autism: a conceptual overview. J Early Int Beh Interven 4:714–735
43.
Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ (2006) Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 16(5):599–610PubMedCrossRef
44.
Zeiner P, Gjevik E, Weidle B (2011) Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder. Acta Paediatr 100:1258–1261PubMedCrossRef
45.
Troost PW, Steenhuis MP, Tuynman-Qua HG et al (2006) Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study. J Child Adolesc Psychopharmacol 16(5):611–619PubMedCrossRef
46.
Arnold LE, Aman MG, Cook AM et al (2006) Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 45(10):1196–1205PubMedCrossRef
47.
Goodman WK, Murphy TK, Storch EA (2007) Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology 191(1):87–96PubMedCrossRef
48.
Fischer M, Barkley RA, Smallish L, Fletcher K (2005) Executive functioning in hyperactive children as young adults: attention, inhibition, response perseveration, and the impact of comorbidity. Dev Neuropsychol 27(1):107–133PubMedCrossRef
49.
Korenblum CB, Chen SX, Manassis K, Schachar RJ (2007) Performance monitoring and response inhibition in anxiety disorders with and without comorbid ADHD. Depress Anxiety 24(4):227–232PubMedCrossRef
50.
Barkley RA (1997) Defiant children: A clinician’s manual for assessment and parent training. Guilford Press, New York
51.
Kazdin AE (2003) Parent training and community-based interventions may benefit children with disruptive behaviour disorders. Evid Based Ment Health 6(3):81PubMedCrossRef
52.
Aman MG (2004) Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder. Semin Pediatr Neurol 11(3):225–228PubMedCrossRef
53.
Brookman-Frazee L, Stahmer A, Baker-Ericzen MJ, Tsai K (2006) Parenting interventions for children with autism spectrum and disruptive behavior disorders: opportunities for cross-fertilization. Clin Child Fam Psychol Rev 9(3–4):181–200PubMedCrossRef
54.
Garland AF, Hawley KM, Brookman-Frazee L, Hurlburt MS (2008) Identifying common elements of evidence-based psychosocial treatments for children’s disruptive behavior problems. J Am Acad Child Adolesc Psychiatry 47(5):505–514PubMedCrossRef
55.
van de Wiel N, Matthys W, Cohen-Kettenis PC, van Engeland H (2002) Effective treatments of school-aged conduct disordered children: recommendations for changing clinical and research practices. Eur Child Adolesc Psychiatry 11(2):79–84PubMedCrossRef
Metagegevens
Titel
The Role of Co-Occurring Disruptive Behavior in the Clinical Presentation of Children and Adolescents with Anxiety in the Context of Autism Spectrum Disorders
Auteurs
Eric A. Storch
Elysse B. Arnold
Anna M. Jones
Chelsea M. Ale
Jeffrey J. Wood
Jill Ehrenreich-May
Adam B. Lewin
P. Jane Mutch
Tanya K. Murphy
Publicatiedatum
01-10-2012
Uitgeverij
Springer US
Gepubliceerd in
Child Psychiatry & Human Development / Uitgave 5/2012
Print ISSN: 0009-398X
Elektronisch ISSN: 1573-3327
DOI
https://doi.org/10.1007/s10578-012-0294-1

Andere artikelen Uitgave 5/2012

Child Psychiatry & Human Development 5/2012 Naar de uitgave

Original Article

Somatic Symptoms in Traumatized Children and Adolescents

Original Article

The Contribution of Parenting Practices and Parent Emotion Factors in Children at Risk for Disruptive Behavior Disorders

Original Article

Symptoms of Anxiety and Associated Risk and Protective Factors in Young Asian American Children

Review Paper

Evidence Based Clinical Assessment of Child and Adolescent Social Phobia: A Critical Review of Rating Scales

Original Article

Parental and Late Adolescent Psychopathology: Mothers May Provide Support When Needed Most

Review Paper

Prenatal and Postpartum Maternal Psychological Distress and Infant Development: A Systematic Review